Biomedical Imaging and Computational Modeling in Cardiovascular Disease: Patient-Specific Applications Using Numerical Models

2012 ◽  
pp. 173-192
Author(s):  
Vanessa Díaz-Zuccarini ◽  
Silvia Schievano
Keyword(s):  
Cardiovascular Disease ◽  
Computational Modeling ◽  
Biomedical Imaging ◽  
Numerical Models ◽  
Disease Patient ◽  
Patient Specific

scholarly journals B-PO05-005 MULTI-PHYSICS, PATIENT-SPECIFIC COMPUTATIONAL MODELING OF LA ELECTROPHYSIOLOGY, BIOMECHANICS AND HEMODYNAMICS REVEALS MECHANISTIC CONNECTIONS BETWEEN FIBROTIC REMODELING AND THROMBOSIS RISK

Heart Rhythm ◽  
2021 ◽  
Vol 18 (8) ◽  
pp. S372-S373
Author(s):  
Alejandro Gonzalo ◽  
Christoph M. Augustin ◽  
Manuel García-Villalba ◽  
Pablo Martínez-Legazpi ◽  
Oscar Flores ◽  
...  
Keyword(s):  
Computational Modeling ◽  
Patient Specific ◽  
Thrombosis Risk

scholarly journals Patient-specific computational haemodynamics associated with surgical creation of an arteriovenous fistula

2021 ◽  
Author(s):  
George Hyde-Linaker ◽  
Pauline Hall Barrientos ◽  
Sokratis Stoumpos ◽  
Asimina Kazakidi
Keyword(s):  
Blood Flow ◽  
Flow Rate ◽  
Disease Patient ◽  
Blood Flow Rate ◽  
Fold Increase ◽  
Transitional Flow ◽  
Patient Specific ◽  
Venous Anastomosis ◽  
End Stage

Abstract Despite arteriovenous fistulae (AVF) being the preferred vascular access for haemodialysis, high primary failure rates (30-70%) and low one-year patency rates (40-70%) hamper their use. The haemodynamics within the vessels of the fistula change significantly following surgical creation of the anastomosis and can be a surrogate of AVF success or failure. Computational fluid dynamics (CFD) can crucially predict AVF outcomes through robust analysis of a fistula’s haemodynamic patterns, which is impractical in-vivo. We present a proof-of-concept CFD framework for characterising the AVF blood flow prior and following surgical creation of a successful left radiocephalic AVF in a 20-year-old end-stage kidney disease patient. The reconstructed vasculature was generated utilising multiple contrast-enhanced magnetic resonance imaging (MRI) datasets. Large eddy simulations were conducted for establishing the extent of arterial and venous remodelling. Following anastomosis creation, a significant 2-3-fold increase in blood flow rate was induced downstream of the left subclavian artery. This was validated through comparison with post-AVF patient-specific phase-contrast data. The increased flow rate yielded an increase in time-averaged wall shear stress (TAWSS), a key marker of adaptive vascular remodelling. We have demonstrated TAWSS and oscillatory shear distributions of the transitional-flow in the venous anastomosis are predictive of AVF remodelling.

scholarly journals Variation in end-stage renal disease patient outcomes: what we know, what should we know, and how do we find it out?

1993 ◽  
Vol 3 (11) ◽  
pp. 1738-1747
Author(s):  
P Kurtin ◽  
A R Nissenson
Keyword(s):  
Patient Outcomes ◽  
Outcome Measure ◽  
Disease Patient ◽  
Patient Specific ◽  
Quality Cost ◽  
Current State ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

The size and expense of the ESRD program exceed all predictions made when the program was first initiated. Although the effectiveness of dialytic therapy is unquestioned, its value (quality/cost) is actively debated in this era of constricting resources. To better evaluate the quality of the ESRD program, it is essential to first define and quantitate the outcomes of dialytic care. Although mortality is a convenient outcome measure, it may be affected by many patient-specific as well as other factors that must be considered when evaluating and comparing new and existing technologies or advances. Quality of life is only beginning to be used in depth as an outcome measure, and much work is needed to standardize research methodology and thus move this area forward. The following review describes the current state of knowledge regarding outcomes of ESRD patients and proposes areas for future investigation, which should help increase the understanding of the value of the ESRD program to patients, providers, and payors.

Abstract 427: A Patient-Specific 3D Bioprinted Platform for in vitro Disease Modeling and Treatment Planning in Pulmonary Vein Stenosis

2020 ◽  
Vol 127 (Suppl_1) ◽  
Author(s):  
Vahid Serpooshan ◽  
Martin L Tomov ◽  
Akaash Kumar ◽  
Bowen Jing ◽  
Sai Raviteja Bhamidipati ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Pulmonary Vein ◽  
Disease Modeling ◽  
Unmet Need ◽  
Cfd Modeling ◽  
Pulmonary Vein Stenosis ◽  
Patient Specific ◽  
Clinical Interventions ◽  
Vein Stenosis

Pulmonary vein stenosis (PVS) is an acute pediatric cardiovascular disease that is always lethal if not treated early. While current clinical interventions (stenting and angioplasties) have shown promising results in treating PVS, they require multiple re-interventions that can lead to re-stenosis and diminished long-term efficacy. Thus, there is an unmet need to develop functional in vitro models of PVS that can serve as a platform to study clinical interventions. Patient-inspired 3D bioprinted tissue models provide a unique model to recapitulate and analyze the complex tissue microenvironment impacted by PVS. Here, we developed perfusable in vitro models of healthy and stenotic pulmonary vein by 3D reconstruction and bioprinting inspired by patient CT data ( Figure 1 ). Models were seeded with human endothelial (ECs) and smooth muscle cells (SMCs) to form a bilayer structure and perfused using a bioreactor to study cell response to stenotic geometry, and to the stent-based treatment. Flow hemodynamics through printed veins were quantified via Computational Fluid Dynamics (CFD) modeling, 4D MRI and 3D Ultrasound Particle Imaging Velocimetry (echo PIV). Cell growth and endothelialization were analyzed. Our work demonstrates the feasibility of bioprinting various cardiovascular cells, to create perfusable, patient-specific vascular constructs that mimic complex in vivo geometries. Deeper understanding of EC-SMC crosstalk mechanisms in in vitro biomimetic models that incorporate tissue-like geometrical, chemical, and biomechanical ques could offer substantial insights for prevention and treatment of PVS, as well as other cardiovascular disease.

scholarly journals The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma

Blood ◽  
1994 ◽  
Vol 84 (10) ◽  
pp. 3283-3290 ◽  
Author(s):  
RA Vescio ◽  
CH Hong ◽  
J Cao ◽  
A Kim ◽  
GJ Schiller ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Heavy Chain ◽  
Disease Patient ◽  
Patient Specific ◽  
Specific Marker ◽  
Malignant Cells ◽  
Assay Sensitivity ◽  
Hematopoietic Stem ◽  
Ig Heavy Chain

Abstract Autologous stem cell transplantation has become an important therapy in multiple myeloma (MM). To develop adequate autograft purging methods, it is necessary to determine whether antigens expressed on early hematopoietic progenitors exist on malignant cells. The Ig heavy chain produced by the MM cells shows evidence of prior somatic mutation without intraclonal diversity. As a result, this sequence can be used as a specific marker to detect all members of the malignant clone. The Ig heavy chain sequence expressed by the MM cells was obtained in five patients with advanced disease. Patient specific oligonucleotide primers were designed based on the complementarity determining regions (CDR) of each MM Ig sequence and used to amplify DNA by polymerase chain reaction for the detection of malignant cells. A highly purified collection of CD34+ cells was obtained after passage of the initial bone marrow cells through an immunoadsorption column and fluorescence- activated cell sorting. Despite an assay sensitivity of 1 tumor cell in 2,500 to 44,000 normal cells, none of the CD34+ samples showed product with the myeloma-specific CDR primers. Therefore, positive selection for cells bearing this antigen should yield a tumor-free autograft capable of providing hematopoietic recovery after myeloablative chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document